# A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

> **NCT06817343** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Exegenesis Bio** · enrollment: 12 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD)
- Neovascular (Wet) Age-related Macular Degeneration (AMD)

## Interventions

- **BIOLOGICAL:** Aflibercept (2.0 mg)

## Key facts

- **NCT ID:** NCT06817343
- **Lead sponsor:** Exegenesis Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06817343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06817343, "A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06817343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*